Synthesis and structure-activity relationships of 3-phenyl-2-propenamides as inhibitors of glycogen phosphorylase a

Bioorganic and Medicinal Chemistry Letters

Volumn 16, Issue 22, 2006, Pages 5892-5896

  Li, Yue H ^a   Coppo, Frank T ^a   Evans, Karen A ^a   Graybill, Todd L ^a   Patel, Mehul ^a   Gale, Jennifer ^a   Li, Hu ^a   Tavares, Francis ^a   Thomson, Stephen A ^a  

^a GLAXOSMITHKLINE   (United States)

Author keywords

Human liver glycogen phosphorylase; Solid phase synthesis

Indexed keywords

3 PHENYL 2 PROPENAMIDE DERIVATIVE; AMIDE; GLYCOGEN PHOSPHORYLASE B; GLYCOGEN PHOSPHORYLASE B INHIBITOR; GLYCOSYLTRANSFERASE INHIBITOR; UNCLASSIFIED DRUG;

ARTICLE; DRUG EFFECT; DRUG STRUCTURE; DRUG SYNTHESIS; ENZYME ACTIVITY; ENZYME INHIBITION; IC 50; PHARMACOPHORE; SOLID PHASE SYNTHESIS; STRUCTURE ACTIVITY RELATION;

ACRYLAMIDES; COMBINATORIAL CHEMISTRY TECHNIQUES; DRUG DESIGN; DRUG EVALUATION, PRECLINICAL; ENZYME INHIBITORS; GLYCOGEN PHOSPHORYLASE; HUMANS; LIVER; RESINS, SYNTHETIC; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 33749318517     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2006.08.055     Document Type: Article

References (28)

1. Treadway J.L., Mendys P., and Hoover D.J. Exp. Opin. Invest. Drugs 10 (2001) 439 and references therein
2. Martin W.H., Hoover D.J., Armento S.J., Stock I.A., McPherson R.K., Danley D.E., Stevenson R.W., Barrett E.J., and Treadway J.L. Proc. Natl. Acad. Sci. U.S.A. 95 (1998) 1776
3. Chen J., Liu J., Zhang L., Wu G., Hua W., Wu X., and Sun H. Bioorg. Med. Chem. Lett. 16 (2006) 2915
4. Klabunde T., Wendt K.U., Kadereit D., Brachvogel V., Burger H.-J., Herling A.W., Oikonomakos N.G., Kosmopoulou M.N., Schmoll D., Sarubbi E., Von Roedern E., Schoenafinger K., and Defossa E. J. Med. Chem. 48 (2005) 6178
5. Dudash J., Zhang Y., Moore J.B., Look R., Liang Y., Beavers M.P., Conway B.R., Rybczynski P.J., and Demarest K.T. Bioorg. Med. Chem. Lett. 15 (2005) 4790
6. Wright S.W., Rath V.L., Genereux P.E., Hageman D.L., Levy C.B., McClure L.D., McCoid S.C., McPherson R.K., Schelhorn T.M., Wilder D.E., Zavadoski W.J., Gibbs E.M., and Treadway J.L. Bioorg. Med. Chem. Lett. 15 (2005) 459
7. Oikonomakos N.G., Kosmopoulou M.N., Chrysina E.D., Leonidas D.D., Kostas I.D., Wendt K.U., Klabunde T., and Defossa E. Protein Sci. 14 (2005) 1760
8. Kristiansen M., Andersen B., Iversen L.F., and Westergard N. J. Med. Chem. 47 (2004) 3537
9. Rosauer K.G., Ogawa A.K., Willoughby C.A., Ellsworth K.P., Geissler W.M., Myers R.W., Deng Q., Chapman K.T., Harris G., and Moller D.E. Bioorg. Med. Chem. Lett. 13 (2003) 4385
10. Lu Z., Bohn J., Bergeron R., Deng Q., Ellsworth K.P., Geissler W.M., Harris G., McCann P.E., McKeever B., Myers R.W., Saperstein R., Willoughby C.A., Yao J., and Chapman K. Bioorg. Med. Chem. Lett. 13 (2003) 4125
11. Rath V.L., Ammirati M., Danley D.E., Ekstrom J.L., Gibbs E.M., Hynes T.R., Mathiowetz A.M., McPherson R.K., Olson T.V., Treadway J.L., and Hoover D.J. Chem. Biol 7 (2000) 677
12. Tsitsanou K.E., Skamnaki V.T., and Oikonomakos N.G. Arch. Biochem. Biophys. 384 (2000) 245
13. Zographos S.E., Oikonomakos N.G., Tsitsanou K.E., Leonidas D.E., Chrysina E.D., Skamnaki V.T., Bischoff H., Goldmann S., Watson K.A., and Johnson L.N. Structure 5 (1997) 1413
14. 50 values given are average values of at least two replicates. See WO06/52722 for additional details.
15. The Robbins Flex-Chem system can be purchased from SciGene.
16. Typical product ratio for these reactions was 30% desired product and 70% cyclized by product.
17. Synthesis of related 3-phenyl-2-propenamides via solid-phase using (4-formyl-3-methoxyphenoxy)benzyl polystyrene resin is reported in the literature in. Weber C., Bielik A., Szendrei G.I., Keseru G.M., and Greiner I. Bioorg. Med. Chem. Lett. 14 (2004) 1279 but without an amine, as in intermediate 5, for further functionalization
18. The resin was obtained from Polymer Laboratories, 1.5 mmol/g (PL-FDMP, Product # 1466, 150-300 μm).
19. Wang Y., Jin J., Moore M.L., Graybill T.L., Wang F., Wang M.A., Wang B., Jin Q., and Rivero R.A. Tetrahedron Lett. 45 (2004) 6645
20. 2O containing 0.02% TFA (3.6 min gradient) and monitored by a UV detector operating at 214 nm and by a SEDEX 75 evaporative light scattering detector (ELSD) operating at 42 °C. LC-MS M+H signals were consistent with expected molecular weight for all reported products.
21. 2O, 0.1% TFA) with UV detection at 254 nm was used.
22. Nishikawa Y., Shindo T., Ishii K., Nakamura H., Kon T., and Uno H. Chem. Pharm. Bull. 37 (1989) 100
23. Carmignani M., Volpe A.R., Botta B., Espinal R., DeBonnevaux S.C., Peluca C., Botta M., Corelli F., Tafi A., Sacco R., and Monache G.D. J. Med. Chem. 44 (2001) 2950
24. Corelli F., Dei D., Monache G.D., Botta B., DeLuca C., Carmignani M., Volpe A.R., and Botta M. Bioorg. Med. Chem. Lett. 6 (1996) 653
25. Berkhout T.A., Blaney F.E., Bridges A.M., Cooper D.G., Forbes I.T., Gribble A.D., Groot P.H.E., Hardy A., Ife R.J., Kaur R., Moores K.E., Shillito H., Willetts J., and Witherington J. J. Med. Chem. 46 (2003) 4070
26. Witherington J., Bordas V., Cooper D.G., Forbes I.T., Gribble A.D., Ife R.J., Berkhout T., Gohil J., and Groot P.H.E. Bioorg. Med. Chem. Lett. 11 (2001) 2177
27. Hackling A., Ghosh R., Perachon S., Mann A., Holtje H.-D., Wermuth C.G., Schwartz J.-C., Sippl W., Sokoloff P., and Stark H. J. Med. Chem. 46 (2003) 3883
28. Compounds were measured in an artificial phospholipid bilayer system using aqueous phosphate buffer, pH 7.05. Compounds of interest are spiked to the donor sides, and after a set time point the samples are withdrawn and analyzed by HPLC with UV detection. The assay detection limit is 3 nm/s.